Search

Your search keyword '"Scarsi M"' showing total 17 results
Start Over Author "Scarsi M" Publisher bmj
17 results on '"Scarsi M"'

15. Response to: 'Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'' by Kawada.

Author

Piantoni S, Andreoli L, Colombo E, Mendeni M, Ghirardelli ML, Brucato A, Imazio M, Furloni R, Franceschini F, Airó P, and Scarsi M

Subjects
Humans, Adult, Colchicine therapeutic use, SARS-CoV-2, COVID-19, Respiratory Distress Syndrome drug therapy
Abstract

Competing Interests: Competing interests: None declared.

Published
2023
Full Text
View/download PDF

16. Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: 'Colchicine treatment in community healthcare setting to prevent severe COVID-19' by Della-Torre et al .

Author

Piantoni S, Colombo E, Furloni R, Andreoli L, Brucato A, Imazio M, Airó P, and Scarsi M

Subjects
Anti-Inflammatory Agents therapeutic use, Anti-Inflammatory Agents, Non-Steroidal, Community Health Services, Humans, COVID-19, Colchicine therapeutic use
Abstract

Competing Interests: Competing interests: None declared.

Published
2022
Full Text
View/download PDF

17. Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome.

Author

Scarsi M, Piantoni S, Colombo E, Airó P, Richini D, Miclini M, Bertasi V, Bianchi M, Bottone D, Civelli P, Cotelli MS, Damiolini E, Galbassini G, Gatta D, Ghirardelli ML, Magri R, Malamani P, Mendeni M, Molinari S, Morotti A, Salada L, Turla M, Vender A, Tincani A, Brucato A, Franceschini F, Furloni R, and Andreoli L

Subjects
Aged, Aged, 80 and over, Antiviral Agents therapeutic use, Betacoronavirus, COVID-19, Case-Control Studies, Cohort Studies, Coronavirus Infections complications, Coronavirus Infections mortality, Dexamethasone therapeutic use, Drug Combinations, Enzyme Inhibitors therapeutic use, Female, Hospitalization, Humans, Hydroxychloroquine therapeutic use, Italy, Lopinavir therapeutic use, Male, Middle Aged, Pandemics, Pneumonia, Viral complications, Pneumonia, Viral mortality, Proof of Concept Study, Proportional Hazards Models, Respiratory Distress Syndrome etiology, Respiratory Distress Syndrome mortality, Ritonavir therapeutic use, SARS-CoV-2, Survival Rate, COVID-19 Drug Treatment, Anti-Inflammatory Agents therapeutic use, Colchicine therapeutic use, Coronavirus Infections drug therapy, Pneumonia, Viral drug therapy, Respiratory Distress Syndrome drug therapy
Abstract

Objectives: The outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, colchicine was proposed to patients with COVID-19, and its effects compared with 'standard-of-care' (SoC)., Methods: In the public hospital of Esine, northern Italy, 140 consecutive inpatients, with virologically and radiographically confirmed COVID-19 admitted in the period 5-19 March 2020, were treated with 'SoC' (hydroxychloroquine and/or intravenous dexamethasone; and/or lopinavir/ritonavir). They were compared with 122 consecutive inpatients, admitted between 19 March and 5 April 2020, treated with colchicine (1 mg/day) and SoC (antiviral drugs were stopped before colchicine, due to potential interaction)., Results: Patients treated with colchicine had a better survival rate as compared with SoC at 21 days of follow-up (84.2% (SE=3.3%) vs 63.6% (SE=4.1%), p=0.001). Cox proportional hazards regression survival analysis showed that a lower risk of death was independently associated with colchicine treatment (HR=0.151 (95% CI 0.062 to 0.368), p<0.0001), whereas older age, worse PaO2/FiO2, and higher serum levels of ferritin at entry were associated with a higher risk., Conclusion: This proof-of-concept study may support the rationale of use of colchicine for the treatment of COVID-19. Efficacy and safety must be determined in controlled clinical trials., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results